aHUS serum induces C3 and C5b-9 deposition on

Dynamics of complement activation in aHUS and how to
monitor eculizumab therapy
by Marina Noris, Miriam Galbusera, Sara Gastoldi, Paolo Macor, Federica Banterla,
Elena Bresin, Claudio Tripodo, Serena Bettoni, Roberta Donadelli, Elisabetta Valoti,
Francesco Tedesco, Alessandro Amore, Rosanna Coppo, Piero Ruggenenti, Eliana
Gotti, and Giuseppe Remuzzi
Blood
Volume 124(11):1715-1726
September 11, 2014
©2014 by American Society of Hematology
Immunohistochemical analysis of C3 and C9 (C5b-9) staining in kidney biopsy specimens from
aHUS patients.
Marina Noris et al. Blood 2014;124:1715-1726
©2014 by American Society of Hematology
aHUS serum induces C3 and C5b-9 deposition on microvascular endothelial cells (HMEC-1).
Marina Noris et al. Blood 2014;124:1715-1726
©2014 by American Society of Hematology
Effect of complement inhibitors on aHUS serum-induced C3 and C5b-9 deposition on ADPactivated HMEC-1.
Marina Noris et al. Blood 2014;124:1715-1726
©2014 by American Society of Hematology
Serum from healthy carriers of complement gene mutations induces C3 and C5b-9 deposition on
ADP-activated microvascular endothelial cells (HMEC-1).
Marina Noris et al. Blood 2014;124:1715-1726
©2014 by American Society of Hematology
Effect of eculizumab on clinical and complement parameters in case 5.
Marina Noris et al. Blood 2014;124:1715-1726
©2014 by American Society of Hematology
Effect of eculizumab on clinical and complement parameters in case 7.
Marina Noris et al. Blood 2014;124:1715-1726
©2014 by American Society of Hematology